Full-Time

Field Medical Director

Oncology

Posted on 9/13/2025

Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$169.7k - $282.9k/yr

+ Bonus + Share-based Long Term Incentive Program

No H1B Sponsorship

Florida, USA

Remote

Candidate must be based in Florida.

Category
Medical, Clinical & Veterinary (1)
Required Skills
Data Analysis
Requirements
  • Bachelor’s degree in a health science required
  • Relevant experience required: PharmD/PhD with 5+ years of experience, MBA/MSc with 7+ years of experience, BA/BSc with 8+ years of experience
  • Demonstrate excellent oral and written communication skills
  • Demonstrate excellent interpersonal skills: ability to understand and respond to multiple external and internal customers’ demands and manage and handle conflict constructively
  • Demonstrate ability to manage a significant volume of projects developed in a remote environment, while exhibiting the ability to prioritize, successfully implement, and demonstrate excellent judgment skills and work in a continuous improvement environment
  • Valid US driver’s license and driving record in compliance with company standards. Any DUI/DWI or other impaired driving citation within the past 7 years will disqualify you from being hired
Responsibilities
  • Plan and execute Medical strategy and engagement for appropriate assigned customers within a territory, compliantly coordinating with other Pfizer colleagues as needed to achieve Medical objectives
  • Maintain required level of knowledge of relevant TA/disease states and Pfizer medicines, providing therapeutic area/product information to both internal and external stakeholders as needed
  • Serve as a conduit and resource for Medical Information and customer insights, providing requested information to HCPs as allowed by Pfizer guidance and sharing customer viewpoints with Pfizer as appropriate
  • Understand the priorities of Pfizer Medical Affairs in order to contribute to Medical content strategy development and execute aligned Field Medical tactics
  • Maintain effective and appropriate communication and collaboration among headquarters Medical colleagues, Medical Information, and other Pfizer Field Medical colleagues
  • Demonstrate expertise in communication across multiple channels, including, but not limited to, live and virtual presentations in small or large settings, written communication, and telephone or virtual conversations
  • Optimize patient centricity of Medical communications and deliverables, incorporating Health Literacy and cultural awareness principles to ensure that patients remain the ultimate focus
  • Deliver approved medical content about Pfizer medicines and relevant topics in the designated therapeutic area
  • Identify and seek medical engagement from priority customer segments in assigned Therapeutic Area
  • Provide truthful, accurate, and scientifically supported information in response to direct unsolicited medical requests from HCPs in a manner that complies with all applicable Pfizer guidelines, policies, and procedures
  • Leads advisory boards (BRF,Vendor) with manager oversight
  • Field relevant inbound queries from HCPs via established triage process
  • In collaboration with Global Medical Affairs colleagues, partner with Oncology Research & Development and Global Product Development (GPD) in the identification of potential sites for Pfizer-sponsored clinical trials, including identification of sites serving under-represented patient populations in trials
  • Appropriately provide Medical support throughout the Investigator Sponsored Research (ISR) process
  • Cultivate research and therapeutic area expertise, including familiarity with latest congress data and disease state literature
  • Provides Asset leadership
  • Understand the principles of study design, methodology, data analysis, and interpretation and communicate these concepts with customers
  • Strong territory leadership
  • Reactively and proactively communicate with local Patient Advocacy Group(s), as appropriate, in close collaboration with Corporate Affairs and HQ Medical Affairs
  • Deliver insights on local patient organization structure, capabilities, and patient population needs
  • Serve on Medical and/or TA and asset cross-functional committees, as appropriate
  • Represent Pfizer Medical Affairs leadership with clinical/professional associations and/or societies, consistently demonstrating medical professionalism in all interactions
  • Mentorship – Onboarding partner, ad board and study lead mentor
  • Participate in special projects as needed
Desired Qualifications
  • Familiarity with internal/external SOPs/Rules/Regulations regarding Pfizer/customer interactions and relationships, etc.
  • Previous Field Medical experience

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Simplify Jobs

Simplify's Take

What believers are saying

  • Oncology biosimilars grow 52% operationally in Q1 2026 amid high-margin expansion.
  • ELREXFIO Phase 3 data supports earlier multiple myeloma treatment positioning.
  • PF-08653944 advances to 10 Phase 3 trials in 2026 with 9.6mg dose.

What critics are saying

  • Eliquis patent expires 2028, generics erode $6B annual revenue 70% in 12 months.
  • Ibrance generics launch 2027, slash $5B sales 60-80% within 18 months.
  • Danuglipron discontinued April 2025 after liver injury in early trials.

What makes Pfizer unique

  • VEPPANU secures FDA approval as first PROTAC therapy for ESR1-mutated breast cancer.
  • VYNDAMAX patent settlements extend US exclusivity to June 2031.
  • PF-08653944 achieves 12.3% placebo-adjusted weight loss monthly in Phase 2b VESPER-3.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Company News

Pfizer
May 4th, 2026
Esperion Therapeutics Completes $22.75 M Series A Financing | Pfizer

ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich

Yahoo Finance
Apr 9th, 2026
Pfizer beats Q4 revenue estimates by 5.5% as branded pharma sector faces mixed earnings

Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.

Yahoo Finance
Apr 7th, 2026
Pfizer stock seen as undervalued buy despite pipeline growth and strategic acquisitions

Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.

Yahoo Finance
Apr 6th, 2026
Pfizer shares climb 7.1% in six months as organic revenue grows 10.1% annually

Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.

Yahoo Finance
Mar 30th, 2026
Pfizer shares up 25% since Jim Cramer said 'pass' on Mad Money

Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.

INACTIVE